B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $11

Benzinga · 01/07 17:49
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $13 to $11.